HYDERABAD: Aurobindo Pharma on Monday mentioned it has commissioned 4 state-of-the-art manufacturing services for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable merchandise and Granulation, by way of its wholly owned subsidiaries. Penicillin-G (Pen-G) facility, situated in a SEZ at Kakinada in Andhra Pradesh, has a manufacturing capability of 15,000 tonne each year and likewise 1.8 lakh tonne of gulcose, whereas 6-Amino Penicillanic Acid plant has a capability to supply 3,600 tonne yearly, the drug maker mentioned in a press launch.
The Rs 2,400 crore Pen-G plant is predicted to start out trial manufacturing in April and business manufacturing in a few months and the ramping up of the manufacturing will occur in the course of the second quarter of the present fiscal, a senior official of the city-based drug maker had earlier mentioned.
The plant was accepted beneath the Manufacturing Linked Incentive (PLI) Scheme for Promotion of Home Manufacturing of Important Key Beginning Supplies (KSMs)/Drug Intermediates and Energetic Pharmaceutical Elements (APIs) within the nation.
The injectable plant has the capability to supply 285 tens of millions of Vials/Ampoules yearly and the Granulated merchandise plant will produce 13,200 tonne yearly, Aurobindo mentioned.
The Rs 2,400 crore Pen-G plant is predicted to start out trial manufacturing in April and business manufacturing in a few months and the ramping up of the manufacturing will occur in the course of the second quarter of the present fiscal, a senior official of the city-based drug maker had earlier mentioned.
The plant was accepted beneath the Manufacturing Linked Incentive (PLI) Scheme for Promotion of Home Manufacturing of Important Key Beginning Supplies (KSMs)/Drug Intermediates and Energetic Pharmaceutical Elements (APIs) within the nation.
The injectable plant has the capability to supply 285 tens of millions of Vials/Ampoules yearly and the Granulated merchandise plant will produce 13,200 tonne yearly, Aurobindo mentioned.
